Bobbie Graham
Overview
Explore the profile of Bobbie Graham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
234
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
MacBrayne C, Rutstein R, Wiznia A, Graham B, Alvero C, Fairlie L, et al.
AIDS
. 2021 Apr;
35(9):1413-1421.
PMID: 33831904
Objective: To describe the pharmacokinetics, safety, and efficacy of etravirine (ETR) in HIV-infected children 1 to less than 6 years of age. Design: Phase I/II, open-label, multicenter, dose-finding study. Methods:...
2.
Owor M, Tierney C, Ziemba L, Browning R, Moye J, Graham B, et al.
Pediatr Infect Dis J
. 2021 Jan;
40(5):446-452.
PMID: 33464021
Background: Severe acute malnutrition (SAM) may alter the pharmacokinetics (PK), efficacy, and safety of antiretroviral therapy. The phase IV study, IMPAACT P1092, compared PK, safety, and tolerability of zidovudine (ZDV),...
3.
Clarke D, Lommerse J, Acosta E, Cababasay M, Wang J, Spector S, et al.
J Acquir Immune Defic Syndr
. 2020 Sep;
85(5):626-634.
PMID: 32925360
Background: HIV treatment of neonates requires identifying appropriate antiretroviral dosing regimens. Our aims were to characterize raltegravir elimination kinetics in low birth weight (LBW) neonates after maternal dosing and to...
4.
Krogstad P, Samson P, Acosta E, Moye J, Townley E, Bradford S, et al.
J Pediatric Infect Dis Soc
. 2020 May;
10(2):201-204.
PMID: 32448902
Clinical Trials Registration: NCT01751568.
5.
Clarke D, Acosta E, Cababasay M, Wang J, Chain A, Teppler H, et al.
J Acquir Immune Defic Syndr
. 2020 Jan;
84(1):70-77.
PMID: 31913995
Background: Adequate pharmacokinetic and safety data in neonates are lacking for most antiretroviral agents. Raltegravir is a selective HIV-1 integrase strand transfer inhibitor available in a granule formulation suitable for...
6.
Viani R, Ruel T, Alvero C, Fenton T, Acosta E, Hazra R, et al.
J Pediatric Infect Dis Soc
. 2019 Apr;
9(2):159-165.
PMID: 30951600
Background: P1093 is an ongoing phase I/II multicenter open-label study of dolutegravir plus an optimized background regimen in age-defined pediatric cohorts; here we report the long-term safety and virologic efficacy...
7.
Hanan N, Paul M, Huo Y, Kapetanovic S, Smith E, Siberry G, et al.
Front Pediatr
. 2019 Feb;
7:16.
PMID: 30788337
Due to potential disease and drug interactions, the appropriate sertraline starting dose and titration range may require adjustment in pediatric patients living with HIV. This is the first report of...
8.
Huang L, Carey V, Lindsey J, Marzan F, Gingrich D, Graham B, et al.
PLoS One
. 2017 Oct;
12(10):e0186589.
PMID: 29065172
Background: The antiretroviral drug nevirapine and the antimalarial artemisinin-based combination therapy artemether-lumefantrine are commonly co-administered to treat malaria in the context of HIV. Nevirapine is a known inhibitor of cytochrome...
9.
Melvin A, Montepiedra G, Aaron L, Meyer 3rd W, Spiegel H, Borkowsky W, et al.
Pediatr Infect Dis J
. 2016 Oct;
36(1):53-60.
PMID: 27749649
Background: Human immunodeficiency virus (HIV)-infected children receiving antiretroviral therapy (ART) have increased prevalence of hyperlipidemia and risk factors for cardiovascular disease. No studies have investigated the efficacy and safety of...
10.
Cressey T, Hazra R, Wiznia A, Foca M, Jean-Philippe P, Graham B, et al.
Pediatr Infect Dis J
. 2016 Sep;
35(12):1333-1335.
PMID: 27583590
HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior...